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A b s t r a c t  
The main aim of this investigation was to develop a sustained release matrix tablets of Tramadol 
HCl using hydrophilic polymers such as hydroxyl propyl methyl cellulose (HPMC), in different grades 
(E15LV, K4M, K100M) and compare the various parameters against the natural polysaccharide 
Okra gum. The polymer proportions are used in different concentration in order to optimize the 
correct proportion of polymer to achieve controlled release profile. The matrix tablets were prepared 
by direct compression technique which is more industrially relevant. A small quantity of Carbopol 
was also incorporated in the formulation to give bio-adhesiveness & improved compression 
characteristics. The formulations were studied for pre-compression parameters and post-
compression parameters. The in vitro drug release study was performed in 0.1N HCl (pH 1.2) for 1.5 
hour and phosphate buffer (pH 6.8) were upto 12 hours. The study results revealed that the matrix 
tablet can be developed with the used polymers without any tablet manufacturing defects in 
optimized polymer concentration.. The polymers could control the drug release in various levels 
according to the concentration present in the formulation. The drug release profile was fitted with 
various pharmacokinetics models. The formulations showed the different degree of fit with different 
kinetic models. The drug release mechanism involves the combined process of diffusion, swelling 
and erosion. 
Keywords: Tramadol HCl, HPMC E15LV, HPMC K4M, HPMC K100M, Okra gum, Matrix  tablets. 
Introduction 
Oral delivery of drugs is by far the most preferable route of drug 
delivery due to the ease of administration, patient compliance and 
flexibility in formulation, etc. The drug delivery systems, available in 
the market are mostly of oral drug delivery systems. Oral drug 
delivery systems have progressed from immediate release to site-
specific delivery over a period of time. The kinetics of drug release 
will be dependent on the specific prolonged action mechanism 
utilized in manufacturing the controlled release system. The effort 
to develop a delivery system that release drug slowly must be 
directed primarily at altering the release rate by affecting the value 
of K1 (K1 = First order rate constant for drug release. [1] The 
controlled release system is to deliver a constant supply of the 
active ingredient, usually at a zero-order rate, by continuously 
releasing, for a certain period of time, an amount of the drug 
equivalent to the eliminated by the body 
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory 
disorder that may affect many tissues and organs, but principally 
attacks flexible (synovial) joints. About 1% of the world's population 
is afflicted by rheumatoid arthritis, women three times more often 
than men. Onset is most frequent between the ages of 40 and 50, 
but people of any age can be affected. [2, 3] The pathology of the 
disease process often leads to the destruction of articular cartilage 
and ankylosis (fusion) of the joints. Rheumatoid arthritis can also 
produce diffuse inflammation in the lungs, membrane around the 
heart (pericardium), the membranes of the lung (pleura), and white 
of the eye (sclera), and also nodular lesions, most common 
in subcutaneous tissue. Although the cause of rheumatoid arthritis 
is unknown, autoimmunity plays a pivotal role in both its chronicity 
and progression, and RA is considered a systemic autoimmune 
disease. In addition, individuals with the HLA-
DR1 or HLADR4 serotypes have an increased risk for developing 
the disorder. It can be a disabling and painful condition, which can 
lead to substantial loss of functioning and mobility if not adequately 
treated.[4]. Various treatments are available for RA such as Non-
pharmacological treatment includes physical therapy, 
orthoses, occupational therapy and nutritional therapy but these do 
not stop the progression of joint destruction. Analgesic and anti-
inflammatory drugs, including steroids, are used to suppress the 
symptoms, while disease-modifying anti-rheumatic 
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drugs (DMARDs) are required to inhibit or halt the underlying 
immune process and prevent long-term damage.[5]  
Tramadol hydrochloride  is a centrally acting synthetic 
analgesic used to treat moderate to moderately-severe pain.[6] 
The drug has a wide range of applications, including treatment of 
rheumatoid arthritis, restless legs syndrome and fibromyalgia. 
Tramadol is a very weak μ-opiod receptor agonist, 
induces serotonin release, and inhibits the re-
uptake of norepinephrine.[7] Tramadol is converted to O-
desmethylTramadol, a significantly more potent μ-opioid agonist. 
This further distinguishes Tramadol from opioids in general 
(including morphine), which do not possess Tramadol's degree of 
receptor subtype selectivity and which are much stronger opiate-
receptor agonists. Similarly, the habituating properties of Tramadol 
(such as they are) are arguably mainly due to μ-opioid agonism 
with contributions from serotonergic and noradrenergic effects. 
Tramadol is used similarly to codeine, to treat moderate to severe 
pain. Pharmacologically, Tramadol is similar to levorphanol (albeit 
with much lower μ-agonism), both agents have SNRI activity.[8] 
Tramadol is also molecularly similar to venlafaxine (Effexor) and 
has similar SNRI effects, with anti-nociceptive effects.  Half life of 
Tramadol is 5-7 hrs, Bioavailability is 50-60%, Protein binding is 
20%, Elimination half-life is  23 min. Approximately 30% of the 
dose is excreted in the urine as unchanged drug, whereas 60% of 
the dose is excreted as metabolites. Tramadol hydrochloride ER 
tablets should be initiated at a dose of 100 mg once daily and 
titrated up as necessary by 100 mg increments every five days for 
relief of pain and depending upon tolerability. Tramadol 
hydrochloride ER tablets should not be administered at a 
dose exceeding 300 mg per day. The developed ER formulation 
reduces the frequency of administration, increases effectiveness of 
therapy and reduces the chances of adverse effect and 
hypersensitivity of reaction by maintaining the plasma drug 
concentration at the optimum level with in therapeutic range for the 
required period of time.  So the rationale behind the formulation ER 
tablets of Tramadol becomes clear as to reduce dose frequency as 
well as side effects. Since Tramadol is known for its side effects. 
The study is also designed to compare the release profile of the 
novel polymer Okra gum against available  for controlled release 
HPMC grades .[9] 
Natural polymeric gums or mucilage is economical and availability 
and low toxicity are the value added in these categories. The plant 
Abelmoschus esculentus is a tall, erect annual plant commonly 
known as ÂOkraÊ. It is widely cultivated in most tropical countries. 
Abelmoschus esculentus (L) Moench commonly known as okra is 
rich in water extractable polysaccharides that can give high 
viscosity at very small concentrations. The thickening properties of  
okra gum polysaccharides are utilized as a fat substitute in 
chocolate bar cookies, egg white substitute and in frozen dairy 
products.Starch is a major constituent of most plant-based and 
some muscle-based processed food.[10] Many researches in drug 
delivery center on are obtained from plants because of their form of 
applications. Natural gums have been employed as disintegrants, 
emulsifying agents suspending agents  and binders.[11] They have 
been also found useful in developing immediate and sustained 
release preparations.[12] Okra gum, a polysaccharide consisting of 
D-galactose, L-rhamnose and L-galacturonic acid.[13, 14] Okra 
gum is applied as a binder. In a study okra gum has been valued 
as a binder in paracetamol tablet formulations. These formulations 
containing okra gum as a binder demonstrated a faster onset and 
higher amount of plastic deformation than those containing gelatin. 
The crushing strength and disintegration times of the tablets 
increased when higher okra gum binder concentration was used 
while their friability decreased.[15] Although gelatin produced 
tablets with higher crushing strength, okra gum produced tablets 
with longer disintegration times than those containing gelatin. It 
was finally concluded from the results that okra gum may be a 
useful hydrophilic matrixing agent in sustained drug delivery 
devices. It forms a viscous mucilaginous solution in water. This 
attribute has been used in the output of a plasma expander 
Abelmoschus esculentus gum (AEG) has likewise been used as 
suspending and emulsifying agents Recently, the mucilage 
obtained from Abelmoschus esculentus was reported to cause a 
sustained release property in tablet formulations.[16-17] 
HPMC E 15 LV  is hydorxy propyl methyl cellulose ether low 
viscosity grade polymer. Cellulose ether products are available in 
two basic types: methylcellulose and hypromellose. Both types of 
have the polymeric backbone of cellulose, a natural carbohydrate 
that contains a basic repeating structure of anhydroglucose units. 
During the manufacture of HPMC, cellulose fibers are heated with 
a caustic solution which in turn is treated with methyl chloride, 
yielding the methyl ether of cellulose. The fibrous reaction product 
is purified and ground to a fine, uniform powder. Methylcellulose 
(A) is made using only methyl chloride. For hypromellose products 
(E, F and K), propylene oxide is used in addition to methyl chloride 
to obtain hydroxypropyl substitution on the anhydroglucose units. 
This substituent group, -OCH2CH(OH)CH3-, contains a secondary 
hydroxyl on the number two carbon and may also be considered to 
form a proplyene glycol ether of cellulose. These products possess 
varying ratios of hydroxypropyl and methyl substitution, a factor 
which influences organic solubility and the thermal gelation 
temperature of aqueous solutions. Cellulose ethers dissolve in 
water with no sharp solubility limit. This feature provides 
exceptional handling flexibility and control of solubilization rate. 
The scope of this work is to define the competitive controlled 
release properties of  okra gum against the famous controlled 
release  modern versions of polymers  such as HPMC E and K 
grades. The premium version of the HPMC polymers are known for 
their superiority in performance and flexibility in the handling in 
controlled release systems based on matrix and reservoir type of 
mechanism.  In current pharmaceutical industry HPMC is the 
integral part of the novel drug delivery system.[21] This research is 
designed to explore the competitive potential of Okra gum in 
controlled release and extended  drug release systems against the 
already known HPMC different  grades. The tablets are prepared 
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by direct compression since it is industrial relevant.  Okra gum 
being a natural polymer which has many advantages over the  
synthetic and semi synthetic polymers. The study also focused on 
rheumatoid arthritis by using the model drug Tramadol HCl 
because Tramadol is used similarly to codeine to treat moderate to 
severe pain. The controlled release Tramadol HCl devices offers 
the concentration of the drug within the therapeutic window for the 
extended period of time to increase patient convenience,.  
The main objective of the present study is to develop a extended 
release tablets of Tramadol HCl  by using Okra gum and different  
hydrophilic polymers. The extended release tablets were prepared 
by direct compression method which is industrially relevant. The 
polymers such as HPMC K4M, HPMC E15LV, HPMC K100M, 
Carbopol 940, Okra gum, was used in the formulation design. The 
exipients such as Microcrystalline cellulose, Magnesium stearate, 
and Talc were used as an excipients. The evaluation of blend 
characteristics of prepared granules and evaluation of Post ă
compression parameters of Tramadol extended release tablets 
was also carried out. The in vitro release characteristics of all 
formulations were done  by using USP dissolution apparatus type II 
(paddle). The Mechanism of drug release was analysed by using 
various kinetic models and the results were discussed ornately. 
The main objective of the present study is to develop a extended 
release tablets of Tramadol  by using Okra gum and different  
hydrophilic polymers.containing extended release polymers that 
will release the drug for a prolong period thus maintaining plasma 
level for desired time period was designed as the opitimized 
formulation. The extended release tablets were prepared by direct 
compression method which is industrially relevant. The polymers 
such as using HPMC K4M, HPMC E15LV, HPMC K100M, 
Carbopol 940, Okra gum, was used the final design. The exipients 
such as Micro crystalline cellulose, Magnesium stearate, and Talc. 
The evaluation of blend characteristics of prepared granules and 
evaluation of Post ăcompression parameters of Tramadol extended 
release tablets also carried out. The in-vitro release characteristics 
of all formulations were done by using USP dissolution apparatus 
type II (paddle). The Mechanism of drug release was analysed by 
using various kinetic models and released results were presented 
in this article. 
Materials and Methods 
Material 
The materials used in the experiment are of analytical grade. The 
model drug Tramadol Aurobindo pvt. Ltd, Hyderabad, India. HPMC 
K4M, HPMC E15 LV and Carbopol 940 were procured from Loba 
chemie pvt. Ltd Mumbai, India. HPMC K100M was from Otto 
chemicals, Mumbai, India. Magnesium stearate was obtained from 
SD fine-chem. Ltd. Mumbai. Talc and MCC from Merck specialities 
pvt Ltd, Mumbai, India. Okra gum was prepared in the Institute. 
Preformulation study 
The Preformulation study such as identification test, Angle of 
repose, Bulk density, Tapped density, Compressibility  index 
(CarrÊs index), HausnerÊs Ratio were carried out as per the 
standard procedure (Ofoefule et al., 2001). Drug - Excipient 
Compatibility Studies were also performed  by using FTIR and 
DSC analaysis. 
FTIR  study   
The drug polymer interactions were analyzed by FTIR 
spectrophotometer, Perken-Elmer (spectrum-100 Japan). Two 
percent w/w of the sample, with respect to potassium bromide 
(KBr, SD Fine Chem. Ltd, Mumbai India) disc, was mixed with dry 
KBr. The mixture was ground into a fine powder using an agate 
mortar and then compressed into a KBr disc in a hydraulic press at 
a pressure of 10000 Psi. Each KBr disc was scanned 16 times at 
2mm/size at a resolution of 4cm-1 using Carson apodization. The 
characteristic peaks were recorded.[18] 
DSC Differential Scanning Calorimetry study  
DSC thermogram were obtained using an automatic thermal 
analyzer system. Temperature calibration was performed using 
indium as the criterion. Samples were crimped in a standard 
aluminum pan and heated from 50 - 300 Ԩ at a heating rate of 10 
Ԩ/min under constant purging of nitrogen at 30ml/min. An empty 
pan  sealed in the same manner as the sample was used as a 
reference.[19] 
Preparation of Okra gum  
Extraction of mucilage: The fresh Abelmoschus esculentus fruits 
were collected and washed with water. Incisions were made on the 
fruits and left over night.The fruits were crushed and soaked in 
water for 5ă6 hours, boiled for 30 minutes and kept aside for 1 hour 
to allow complete release of the mucilage into the water. The 
mucilage was extracted by using a multi layer muslin cloth bag to 
remove the marc from the solution. Acetone (three times the 
volume of filtrate) was added to precipitate the mucilage. The 
mucilage was separated, dried in an oven at 40ĈC, collected, 
ground, passed through a # 80 sieve and stored in desiccator at 
30ĈC and 45% relative humidity till use.[20] 
Fabrication of extended release tablets of Tramadol HCl 
Extended release tablets containing 100mg of Tramadol HCl were 
prepared by direct compression method by employing HPMC K4M, 
HPMC E15LV, K100M, Carbopol 940 & okra gum  as rate 
controlling polymers, MCC was used as a diluents. Talc and 
Magnesium stearate was used as a glidant and lubricant. All the 
materials were weighed according to the formula given in the Table 
1. Accurately weighed quantity of drug was then mixed thoroughly 
with required quantity of polymers HPMC K4M, HPMC E15LV, 
HPMC K100M and Okra gum as a separate batches. Carbopol940 
was added in each batches in increasing proportion. The diluents 
MCC was added in the formulation and then lubricated with 
Newton et al. International Journal of Drug Delivery 6 (4) 339-350 [2014] 
 
 
  
PAGE | 342 |
 
required quantity of Talc and Magnesium stearate. The powder  
was  then compressed in Rotary tablet punching machine by using 
12mm and 8mm round shaped punches to form a tablets.[22] 
Post-Compression Evaluation  
The post compression parameters such as thickness, Hardness, 
friability, Drug content uniformity, weight variation were analysed 
by standard procedures. [21] 
In-vitro release studies  
Procedure for dissolution. 
The release of Tramadol ER tablet was carried out in USP Type II 
dissolution apparatus 900 ml of 1.2 pH buffer as dissolution 
medium for 1.5 hr at 100 rpm and 37 μ 0.5 oC was maintained 
throughout the experiment. In buffer stage HCl is replaced with 6.8 
pH buffer solution. An aliquot (5 ml) was withdrawn at specific time 
intervals and drug content was determined by UV-visible 
spectrophotometer at 270.5 nm.  An equal volume of fresh 
dissolution medium was replaced to maintain the sink condition. 
Samples were withdrawn at regular time intervals. Drug content 
was determined by UV spectrophotometer at 270.5 NM. 
Cumulative percentage of drug release was calculated by using an 
equation obtained from a standard curve. 
Drug release kinetics and mechanism of drug release 
The dissolution profile of all batches of the formuations was fitted 
with Zero order. First order, Higuchi model and Korsmeyer - 
Peppas model to ascertain the kinetic modeling of drug release. 
Correlation coefficient (R2) values were calculated for linear curves 
obtained by the regression analysis of the drug release model. 
Zero order kinetics, it describes the system in which the drug 
release rate is independent of its concentration.Qt=Q0+K0 t .Where 
the Qt= amount of the drug dissolved in time t and the Q0 = initial 
amount of drug in the solution, which is often zero and K0 is the 
zero order release constant. If the zero order drug release kinetic is 
obeyed , then a plot of Qt versus t will give a straight line with a 
slope of K0 and an intercept at zero. 
In first order kinetics, it describes the drug release from the system 
in which the release rate is concentration dependent. Log Qt =log 
Q0 + Kt/2.303.Where Qt is the amount of drug released in time t. 
Q0 is the initial amount of drug in the solution and K is the first 
order release constant. If the first order drug release kinetic is 
obeyed, then line with a slope of Kt/2.303 and an intercept at t=0 of 
log Q0. 
HiguchiÊs Model 
Drug release from the matrix devices by diffusion has been 
described by HiguchiÊs classical diffusion equation:   Q = [Dε/τ (2A-
CS) CSt] ó. Where, Q = Amount of drug released at timeÂtÊ, D = 
Diffusion coefficient of the drug in the matrix, A = Total amount of 
drug in unit volume of matrix, CS = The solubility of drug in the 
matrix, ε = Porosity of the matrix, τ = Tortuosity, t = Time at which 
amount of drug released. When the data is plotted as Cumulative 
% drug released Vs square root of time yields a straight line, 
indicating that drug release follows diffusion mechanisms. The 
slope is equal to ÂKÊ.[23] 
Korsmeyer ă Peppas model  
The invitro release data were fitted to the well known exponential. 
Which is often used to describe the drug release behaviour from 
polymeric systems. Mt/Mđ = Ktn , Where, Mt/Mđ = The fraction of 
drug released at timeÂtÊ, K = Constant incorporating structural and 
geometrical characteristics of the drug/polymer system, N = 
Diffusion exponent related to the mechanism of drug release. 
When the data plotted as log % drug released Vs log time yields a   
straight line with a slope equal to ÂnÊ and the ÂKÊ can be obtained 
from y-intercept.[24] 
Hixson ă Crowell model 
In Hixson-Crowell cube root law the equation can be written as  
QO1/3 ăQt1/3 = KHC t . Where Qt is the amount of drug release in 
time t, Q0 is the initial amount of the drug in tablet and KHC is the 
rate constant for the Hixson-Crowell rate equation. 
Results and Discussions  
In this study the different grades of Hydroxy Propyl Methyl 
Cellulose (HPMC K4M, HPMC E15LV, HPMC K100M) were used 
for the development of Tramadol HCl extended release tablets (F1-
F9). The natural polysaccharide such as Okra gum also used in the 
development of Tramadol HCl ER and matrix tablets. (F10-F15). 
Every formulation incorporated with the small increments (80, 100 
and 120mg) of Carbopol 940 to improve compression 
characteristics of matrix formulation. It also offers the 
bioadhesiveness for the disintegrated granules. The influence of 
Carbopol 940 was also studied in the drug release profile. The 
excipients such as Microcrystalline cellulose was used as a diluent 
to increase the bulk of the granule. Talc and magnesium stearate 
were used as lubricants in the formulation design. Drug polymer 
interactions and compatibility was studied by comparing FTIR 
spectra of the pure drug with the mixture of drug with other 
ingredients. As shown in Figures 1 & 2. Tramadol HCl exhibited the 
peak at 1176.62cm-1, which indicated the presence of nitrogen 
group. The peaks at 3635.94cm-1 also observed due to the 
presence of inter-molecular hydrogen bonding. The peaks at 
1136.11cm-1 was due to the presence of oxygen. The peaks 
present in the drug, with excipients physical mixture also shows 
and the peaks of Tramadol HCl at 1174.69cm-1, 3699.59cm-1, 
1134.1cm-1 as intact. The frequencies of functional groups of pure 
drug remained unaffected in physical mixture containing different 
polymers and other ingredients. Hence there was no interaction 
between the drug and excipients used in the study.  
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Table 1: Formula of Extended Release tablets of Tramadol HCl 
 
Figure 1: FT-IR Graph of Tramadol HCl (Pure Drug)
 
 
Ingredients (mg/tablet) Formulations 
FT1 FT2 FT3 FT4 FT5 FT6 FT7 FT8 FT9 FT10 FT11 FT12 FT13 FT14 FT15 
Tramadol HCl 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
HPMC K4M 100 125 150 - - - - - - - - - - - - 
HPMC E15LV - - - 125 150 175 - - - - - - - - - 
HPMC K100M - - - - - - 150 175 200 - - - - - - 
Okra gum - - - - - - - - - 25 50 75 100 125 150 
Carbopol 940 80 100 120 80 100 120 80 100 120 80 80 80 80 80 80 
Magnesium stearate 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.2 1.2 1.2 1.2 1.2 1.2 
MCC 114.4 69.4 24.4 101.2 45.8 20.6 14.4 20.1 0.4 89 66 35 16 0.4 0.4 
Talc 4 4 4 4 4 4 4 4 4 3 3 3 3 3 3 
Total weight 400 400 400 411 401.8 421.2 400 400 420 300 300 300 305 300 320 
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Figure 2: FT-IR Graph of Tramadol HCl  + HPMC K4M + Other Excipie
 
This was confirmed by analyzing the drug and used excipients in 
Differential Scanning Calorimetry (DSC) thermograms. The DSC 
Thermograms of the pure drug Tramadol HCl and the mixture of 
drug and other excipients were shown in Figures 3 & 4. A sharp 
melting point transition of  Tramadol HCl pure drug was observed 
at 183■C as endothermic peak. The onset of transition was started 
at 181■C. The thermogram of Tramadol HCl and Carbopol showed 
the endothermic peak at 181.9■C. The thermogram of Tramadol 
HCl and HPMC K4M showed the endothermic peak at 182.7■C. 
The thermogram of Tramadol HCl and Okra gum showed the 
endothermic peak at 184.9■C The endothermic peak of Tramadol 
HCl and HPMC E15LV shows the peak at 182■C. The DSC peak 
value as compared to pure drug and the mixture of samples did not 
affect the drug nature and no major physico chemical changes 
happened to Tramadol HCl. Before the direct compression of the 
tablets the powder was evaluated for angle of repose, tapped 
density, bulk density, compressibility index and hausnerÊs ratio. 
The formulations F1-F3 prepared with HPMC K4M as a prime 
polymer which showed the angle of repose between 21-22 with SD 
of μ0.04-0.06 the compressibility index of these formulations was 
ranged between 29%, 30% and 28% for F1, F2 and F3 
respectively. The HausnerÊs ratio was between 1.3-1.5. The 
formulations[F3-F6] prepared with HPMC E15LV showed the angle 
of repose ranged between 17-23 with the SD of μ0.1-0.5. The 
CarrÊs Index of these formulations were 26, 28 and 33 SD of μ0.24-
0.67 for F4, F5, F6 respectively. The HausnerÊs ratio of these 
formulations ranges between 1.3-1.5. The formulations prepared 
with HPMC K100M[F7-F9], demonstrated the angle of repose 
varied between 26-29 with the SD of μ0.3-0.9. The CarrÊs Index of 
these formulations was 26, 26, 25 for F7, F8, F9 respectively. The 
HausnerÊs ratio of these formulations ranges between 1.2-1.4. The 
formulations (F10-F15) prepared with Okra gum, showed the angle 
of repose between 24-30 with the SD of μ0.1-0.5. The CarrsÊs 
Index of these formulations was 24, 28, 24, 26, 32 SD of μ0.32-
2.57. The HausnerÊs ratio of these formulations ranges between 
1.3-1.5. As shown in Table 2. 
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Figure 3: DSC Thermogram of Tramadol HCl pure drug
 
Figure 4: DSC Overlay spectrum of Tramadol HCl, HPMC K4M, HPMC E15LV, Carbopol   940
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Table 2: Pre compression parameters of the granules 
Batches Angle of 
repose (Ĉ) μ 
SD 
Loose 
bulk 
volume 
Tapped 
bulk 
volume 
Loose Bulk 
Density 
(g/cm3) μ SD 
Tapped bulk 
Density 
(g/cm3) μ SD 
Compressibility 
index (%) 
CarrÊs index 
(%) μ SD 
 
Hausner
ratio 
 
F1 21.8μ0.06 24 17 0.41μ0.001 0.58μ0.003 29.16 29.3μ0.32 1.41
F2 21.8μ0.05 23 16 0.4μ0.002 0.55μ0.001 30.4 27.6μ0.64 1.37
F3 22.8μ0.04 25 18 0.46μ0.001 0.62μ0.020 28 30.4μ2.80 1.55
F4 23.35μ0.1 26 19 0.45μ0.001 0.52μ0.002 26.9 27.14μ0.24 1.44
F5 17.3μ0.2 25 18 0.44μ0.002 0.55μ0.004 28 33.18μ0.26 1.37
F6 22.78μ0.5 24 16 0.46μ0.001 0.62μ0.006 33 30.012μ0.67 1.51
F7 27.69μ0.9 26 19 0.44μ0.003 0.52μ0.01 26.9 23.16μ2.00 1.44
F8 29.11μ0.9 23 17 0.46μ0.003   0.61μ0.01 26.2 23.18μ0.41 1.20
F9 26.19μ0.3 24 18 0.45μ0.002 0.53μ0.008 25.5 26.21μ0.78 1.44
F10 29.03μ0.1 26 17 0.45μ0.002 0.52μ0.008 26.7 30.18μ0.73 1.39
F11 24.03μ0.1 22 19 0.45μ0.002 0.57μ0.002 24.3 23.4μ0.73 1.35
F12 30.59μ0.4 23 18 0.44μ0.003 0.54μ0.002 32 29.12μ2.57 1.32
F13 29.59μ0.4 21 16 0.44μ0.003 0.60μ0.015 28.2 28.16μ2.57 1.43
F14 28.66μ0.5 25 19 0.43μ0.003 0.63μ0.015 30.6 33.16μ0.32 1.35
F15 27.66μ0.5 24 15 0.44μ0.003 0.57μ0.003 24.4 34.03μ0.32 1.53
 
Evaluation of post- compression Parameters 
After the optimization of the pre-compression parameters the 
HPMC and Okra gum based tablets were compressed in 8 mm 
round shaped punches at 16 station Cadmach rotary tablet 
compression machine. The compressed tablets were found to be 
elegant, smooth in appearance. The tablets were not observed with 
any formulation defects such as picking, sticking, capping, 
lamination and cracking. The compressed tablets were evaluated 
for their weight variation, friability, content uniformity, thickness and 
diameter. All the parameters were found to be within the limits. The 
hardness of the formulations F1-F3 was about 5.5-5.8kg/cm2 with 
SD of μ 2.7-3.5.The formulations F4, F5, F6 showed the hardness 
of 5.8-6.18kg/cm2 with SD of μ1.5-3.00. The hardness of the 
formulations F7-F9 was 5.7-5.41 kg/cm2 with SD of μ1-3.60. The 
formulations F10-F15 showed the hardness of 6.08-6.18kg/cm2 
with SD of μ1.5-2.2. The friability of all the formulations was less 
than 1 indicated the good integrity of the tablets during handling 
and packaging. The drug content of the formulation was within the 
pharmacoepial limits which was confirmed by the appropriate 
assay procedure #. The Thickness of the tablets 2.3-2.5 with SD of 
μ0.2-0.23.  for the formulation F1-F9. The formulations F10-F15 
showed the thickness around 4.0-4.5 with SD of μ0.04-0.06 fixing 
the thickness constant. The content uniformity of the tablets was 
made within the limits and weight variation was also controlled. As 
shown in Table 3. 
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Table 3: Post compression parameters of Tramadol HCl ER and matrix tablets 
 
Batches 
Uniformity of weight 
(n=20μSD) (mg) 
Hardness
(n=10μ SD) 
(kg/cm2) 
Friability
(%) 
Thickness
(n=20μ SD) (mm) 
Diameter  
(mm) 
Drug content
(%) 
F1 398μ3.0 5.52μ0.32 0.54μ0.12 2.15μ0.12 12.56 99.29μ0.04 
F2 396μ3.0 5.8μ0.41 0.64μ0.09 2.51μ0.09 12.56 99.46μ0.11 
F3 395μ3.5 5.5μ0.47 0.59μ0.13 2.54μ0.21 12.56 99.66μ0.05 
F4 398μ1.5 5.78μ0.29 0.56μ0.20 2.38μ0.23 12.56 99.23μ0.07 
F5 396μ2.6 5.3μ0.18 0.79μ0.03 2.56μ0.04 12.56 99.49μ0.13 
F6 394μ3.0 6.18μ0.07 0.54μ0.09 2.52μ0.12 12.56 99.72μ0.09 
F7 397μ3.6 5.18μ0.07 0.58μ0.12 2.55μ0.08 12.56 99.29μ0.04 
F8 396μ2.5 5.42μ0.32 0.61μ0.09 2.54μ0.2 12.56 99.46μ0.11 
F9 399μ1.0 5.7μ0.41 0.54μ0.13 2.36μ0.2 12.56 99.66μ0.05 
F10 298μ1.5 6.18μ0.07 0.53μ0.20 4.11μ0.06 8.64 99.23μ0.07 
F11 298μ1.5 6.5μ0.47 0.52μ0.20 4.30μ0.04 8..65 99.23μ0.07 
F12 297μ1.2 6.3μ0.18 0.56μ0.20 4.21μ0.06 8.64 99.49μ0.13 
F13 297μ2.2 6.8μ0.29 0.70μ0.03 4.52μ0.06 8.64 99.49μ0.13 
F14 299μ2.5 6.08μ0.07 0.79μ0.03 4.01μ0.04 8.65 99.72μ0.09 
F15 294μ2.5 6.3μ0.18 0.51μ0.09 4.56μ0.04 8.65 99.72μ0.09 
 
In-Vitro drug release study 
The In-vitro drug release studies were carried out in simulated GIT 
and pH conditions (1.2 and 6.8). The formulations were subjected 
to dissolution studies in 0.1N HCl (1.2 pH) for 1.5h followed by 6.8 
phosphate buffer until the maximum amount of drug was released. 
The formulations F1, F2, and F3 were prepared with HPMC K4M 
and Carbopol 940. The formulation F1(1:1) releases 85% of the 
drug which is extended upto 14h of dissolution profile which 
contains 20% of carbopol as a secondary polymer to offer muco-
adhesiveness and to improve the physico-chemical characteristics 
of the tablet. The Formulation F2(1:1.25) releases the same 
amount(85%) of the drug upto 14h of dissolution study. The 
Formulation F2 showed no significant difference in the dissolution 
characteristics with F1which is containing 25% of Carbopol. The 
Formulation F3 contains the aximum amount of release retarding 
polymer HPMC K4M and Carbopol(30%) shown the slightly 
improved and extended release profile  in the dissolution (80%) 
upto 14h. Among all HPMC K4M  based formulations F3 shown 
controlled release profile compare to other formulations. The 
formulations F4, F5 and F6 were prepared with HPMC E15LV and 
Carbopol 940. Dissolution studies were conducted until the 
maximum amount of drug release. The formulations F4 and F5 
shown 76% and 88% of the drug release respectively, upto 14h of 
dissolution study. The formulation F6 released the drug bit higher 
than F4 indicated that the higher amount of HPMC in the 
preparation controlled the drug release. These formulations also 
contain 20, 25 and 30% of carbopol in the formulae which also 
influenced the controled the release to some extent. The 
formulations F7, F8, F9 controlled the drug release upto 14h. All 
the three formulations[F7, F8 and F9] released almost same 
amount of drug that is 85% upto 14h of dissolution profile. These 
formulations also contains 25, 30, 26% of Carbopol respectively. 
The formulations F10-F15 prepared with Okra gum with the ratio of 
1:0.25, 1:0.5, 1:0.75, 1:1, 1:1.25, 1:1.5. The Okra gum 
concentration were increased proportionately, where as the 
Carbopol concentration was kept constant in all the Okra gum 
based formulation. The formulation design was planned to asses 
the impact of Okra gum on drug release. So that Carbopol 
concentration were kept constant. The formulations F10 and F11 
released was 84% of drug for 14 h. The formulations F12 and F13 
released 82% and 84% of the drug respectively. There was no 
significant retardation observed between F12 and F13. The 
formulation F15 showed highest controlled release which is 75% 
followed by F14 of 81%. Among all the formulations Okra gum also 
shown the competitive controlled release property when compared 
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to commercial synthetic polymers. The physico-chemical properties 
of the Okra gum based tablets was found to be competitive and 
equivalent to the tablets prepared with HPMC polymers of different 
grades. The dissolution profile of triplicate studies were very 
consistent which confirmed the use of Okra gum as a controlled 
release polymer. 
Release Kinetics 
The release kinetics of the formulations were studied by fitting the 
data with different release models. Different formulations were 
shown the different degree of fit for various release mechanisms 
such as Zero order, First order, HiguchiÊs, Korsemeyer PeppaÊs 
and Hixson Crowell models. The formulation F1 showed the 
highest degree of fit with PeppaÊs equation followed by HiguchiÊs 
and Zero order kinetics. The formulation F2 showed the highest 
degree of fit with PeppaÊs kinetics followed by Higuchi and Zero 
order kinetics. In F1 and F2 the release kinetics was also 
influenced by First order and Hixson Crowell kinetics. The 
formulation F3 shown the Hixson Crowell kinetics as the 
predominant release mechanism followed by Zero order and 
HiguchiÊs kinetics. The formulations F4, F5 and F6 showed the 
highest degree of fit with Zero order First order and HiguchiÊs 
kinetics. In F5 Korsemeyer PeppaÊs model was the predominant 
release mechanism. F6, F7 and F8 shown the highest degree of fit 
with Kosemeyer PeppaÊs model followed by HiguchiÊs and Zero 
order kinetics. The formulations prepared with F10-F15 showed the 
Korsemeyer PeppaÊs as the predominant release mechanism 
followed by HiguchiÊs and Zero order kinetics. The mechanism of 
drug release indicates that more than one release mechanism is 
involved in every tablet formulation confirms the complexity in drug 
release mechanism. The involvement of release mechanism in the 
formulated more than one Extended Release tablets confirmed that 
the drug release influenced by the swelling, erosion, diffusion and 
might be by combined mechanism. The Korsmeyer pepllas 
indicates in the Okra gum based formulation confirmed that the 
drug release mechanism was influenced by polymer 
destanglement and geometric changes in the matrix tablets. Which 
also confirmed that Okra gum is the competitive polymer for matrix 
design with the advantages of  hydrophilic nature, swelling, 
mucoadhesiveness and controlled release property which 
confirmed usage of Okra gum as controlled release polymer. As 
shown in Table 4 and Figure 5. 
 
Table 4: Coefficient of correlation (r2) values of different Formulations of Tramadol HCl Extended release tablets. 
 
Formulations 
Zero order First order HiguchiÊs PeppaÊs Hixson 
R2 K0(mg/hr) R2 K1(hr-1) R2 KH R2 N R2 KHC 
F1 0.962 5.106 0.923 0.052 0.968 22.17 0.971 0.555 0.941 0.20 
F2 0.967 5.201 0.918 0.054 0.962 22.44 0.980 0.040 0.924 0.579 
F3 0.965 4.681 0.899 0.046 0.924 21.18 0.911 0.589 0.958 0.263 
F4 0.955 5.25 0.932 0.045 0.881 21.18 0.887 0.746 0.922 0.259 
F5 0.956 5.049 0.997 1.012 0.967 21.98 0.968 0.543 0.918 0.226 
F6 0.977 5.253 0.932 0.048 0.924 22.11 0.980 0.254 0.893 0.496 
F7 0.943 4.790 0.997 1.012 0.974 21.06 0.976 0.540 0.847 0.549 
F8 0.951 4.979 0.876 0.051 0.958 21.63 0.962 0.535 0.953 0.252 
F9 0.958 4.849 0.877 0.046 0.957 20.97 0.973 0.577 0.934 0.437 
F10 0.951 4.887 0.926 0.047 0.926 21.36 0.955 0.526 0.874 0.562 
F11 0.947 4.729 0.892 0.045 0.967 20.67 0.972 0.529 0.894 0.262 
F12 0.971 4.851 0.913 0.044 0.957 20.85 0.962 0.586 0.963 0.589 
F13 0.927 4.806 0.870 0.046 0.927 21.68 0.929 0.582 0.963 0.219 
F14 0.948 4.704 0.900 0.043 0.955 20.43 0.956 0.562 0.870 0.495 
F15 0.977 4.789 0.927 0.041 0.935 20.27 0.944 0.634 0.880 0.495 
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Figure 5: Drug release profile of Tramadol HCl extended release tablets.
 
Stability studies 
The purpose of stability testing is to provide evidence on how the 
quality of a drug substance or drug product varies with time under 
the influence of a variety of environmental factors such as 
temperature, humidity and light. In the present study, Stability study 
was carried out for the optimized formulations according to ICH 
guide lines at 2ă8ĈC (controlled sample), Room temperature and 
40Ĉc / 75% RH for 3 months. Tablets were evaluated for assay, 
hardness and friability after three months. The stability study 
results revealed that there were no significant changes in the 
crucial parameters such as Assay and hardness, which excludes 
the stability problems in the developed formulation. Any how long 
term stability studies are recommended for the formula before the 
final approval. 
Conclusion  
The formulated extended release matrix tablets of Tramadol HCl. 
The extended release tablets showed a sustained release for up to 
14h, indicating a promising potential of the Tramadol HCl ER tablet 
as an alternative to the conventional dosage form. Among the 
formulations (F1, F2, F3) prepared with HPMC K4M and Carbopol 
940 was found to be the best among the formulations (F4, F5, F6) 
prepared with HPMC E15LV and Carbopol 940, F6 was found to 
be the best formulation. Among the formulations F7, F8 and F9 
prepared with HPMC K100M and Carbopol 940, F9 was found to 
be the best formulation. Among the Okra gum based formulations 
F12 and F13 were found to be the best in terms of physio-chemical 
properties of the tablets and controlling the drug release profile. 
Okra gum formulations also competitively showed the controlled 
release as like the cellulose derivative polymers and it is having the 
property of muco-adhesiveness, biocompatibility, which is the 
advantage over the HPMC based formulations. Among all the 
formulations F12 was found to be better in release which follows 
Zero order, Korsemeyer PeppaÊs & followed by Hixson Crowell 
kinetics as a predominant release mechanism. The results of the 
experimental study confirmed that the polymer concentration 
significantly influenced the drug release rate. The tablets of 
optimized formulation F12 (drug polymer ratio of 1:0.75) shown 
82.39 % drug release at the end of 14h indicated that it can extend 
the drug release till the desired time period of 15h. The stability 
studies indicated that the optimized formulation F12 was stable at 
short term stability studies, but long term stability studies has to be 
conducted on tablets to study the changes occurring in various 
storage conditions. Overall study report suggested that Okra gum 
can be successfully used as a controlled release polymer by simple 
industrial relevant direct compression technique.         
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